New Recruiting Trial: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
WHY IT MATTERS
This trial offers a potential new treatment option for patients with recurrent glioblastoma, a condition with very limited treatment choices after initial therapy fails.
Researchers are testing a new drug called JL15003 to see if it can safely treat glioblastoma, a serious brain cancer that has come back after previous treatment. This is an early-stage study that will check both how safe the drug is and whether it helps patients live longer or feel better. The study is now accepting patients and will run starting in April 2026.
NCT ID: NCT07501559 Title: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) Status: RECRUITING Phase: PHASE1, PHASE2 Sponsor: Jecho Biopharmaceuticals Co., Ltd. Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT07501559 Source: UniteRare clinical trials database